Q-omics provides the consensus-scored INTS10 profile across patient tissues and cancer cell-line models. INTS10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, INTS10 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, INTS10 protein abundance shows 30,059 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, THCA, and GBM as cancer lineages where INTS10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS10 survival associations across molecular data types. INTS10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS10 RNA expression–survival associations across cancer types. High INTS10 expression shows unfavorable associations in MESO, KICH, LGG and KIRP, but favorable associations in HNSC and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for INTS10 RNA expression.
This table summarizes INTS10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INTS10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS10 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in READ, STAD and COAD. The THCA box plot shows higher INTS10 RNA expression in normal versus tumor tissue (log2 FC = −0.647, t-test p < 0.001).
This table shows molecular features associated with INTS10 in patient tissues and cancer cell lines. In patient samples, INTS10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
